January, 2018: PepVax Announces Completion of Efficacy Study with Key Pre-Clinical Data to Validate PVX-009, Addition to its Advisory Board and Other Updates... Read more...
October, 2017: PEPVAX, INC. WINS “BEST IN SHOW” AT PHILADELPHIA 1ST PITCH LIFE SCIENCE COMPETITION
Read more...
August, 2017: PEPVAX BEGINS EFFICACY STUDY FOR LEAD CANDIDATE
Read more...
July, 2017: PepVax, Inc., an early stage biotechnology company developing an immunotherapy treatment for triple-negative breast cancer (TNBC), today announced several new milestones and upcoming events that demonstrate the company's continued growth...Read more...